Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 04 September 2018
Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NOCTURNE)
The purpose of this study is to compare the short-term effects of two tolvaptan formulations in patients with ADPKD.
Added 8 years ago
To establish pharmacokinetics (PK), pharmacodynamics (PD), and adverse event (AE) profile of tolvaptan administered as the modified-release (MR) formulation in...
Added 9 years ago
This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. We...
Added 11 years ago
This study's purpose is to evaluate the long-term safety and efficacy of tolvaptan versus placebo in patients with ADPKD.
Added 13 years ago
This study's purpose is to evaluate the long-term safety of open-label tolvaptan regimens to determine the maximally-tolerated dose and acquire...
Added 14 years ago
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.
Standard of care therapies for autosomal dominant polycystic kidney disease (ADPKD) may limit morbidity and mortality due to disease-related complications, but they do not delay disease progression.
Added 11 months ago
Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment.
Autosomal dominant polycystic kidney disease (ADPKD) causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations.
Added 11 months ago
Background: Obesity is thought to increase renal hyperfiltration, thereby increasing albuminuria and the progression of renal disease. The effect of pharmacologically mediated weight loss on renal outcomes is not well-described.
Added 1 month ago
To evaluate the prevalence and characteristics of primary nocturnal enuresis (PNE) in adults in Hong Kong, as there are currently limited epidemiological data in adults.
Added 2 years ago
The epidemiology and factors associated with nocturnal enuresis among boarding and daytime school children in southeast of Turkey: a cross sectional study.
Nocturnal enuresis is an important problem among young children living in Turkey.
Added 2 years ago
This guideline covers diagnosing, assessing, managing and monitoring anaemia in people with chronic kidney disease. It aims to improve care for people with chronic kidney disease by specifying how to...
Added 3 years ago
This guideline covers the care and treatment of people with, or at risk of developing, chronic kidney disease.
Added 4 years ago
The 2013 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease (CKD) provides guidance on lipid management and treatment for all patients with CKD...
Added 5 years ago
|Agency product number||EMEA/H/C/002788|
|Date First Approved||27-05-2015|
|Type||Medicinal product subject to restricted medical prescription|
|Marketing authorisation holder||Otsuka Pharmaceutical Europe Ltd|
|Warnings||This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions|